Skip to content

The middle-term efficacy of RYGB and SG in improving metabolic disorders: a retrospective study based on medical records

The middle-term efficacy of RYGB and SG in improving metabolic disorders

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032602
Enrollment
Unknown
Registered
2020-05-03
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Disorder

Interventions

Group R:post RYGB
Group S:post SG

Sponsors

Shanghai Jiaotong University Affiliated Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing bariatric & metabolic surgery in our hospital. 2. The patients are willing to join in this study and be able to follow the follow-up process . 3. The patients understand and have signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Postoperative drug and / or alcohol abuse. 2. Have major gastrointestinal and pancreatic surgery after bariatric & metabolic surgery (such as any gastrointestinal surgery for resection, revision surgery, etc.); gastrointestinal surgery is permitted including appendectomy, cholecystectomy, liver biopsy, and endoscopic surgery 3. End-stage complications of type 2 diabetes (such as ESRD, etc.) have been combined. 4. Oral steroid hormones, cancer chemotherapy drugs used.

Design outcomes

Primary

MeasureTime frame
BMI;A1c;fast blood glucose;triglyceride;cholesterol;

Secondary

MeasureTime frame
C peptide;insulin;creatinine;

Countries

China

Contacts

Public ContactHongwei Zhang

Department of Metabolic & Bariatric Surgery, Shanghai Jiaotong University Affiliated Sixth People's Hospital

zhw00sub@163.com+86 13917135942

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026